Trial Profile

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 14 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Golcadomide (Primary) ; Prednisone (Primary) ; Rituximab (Primary) ; Vincristine (Primary)
Indications B-cell lymphoma; Diffuse large B cell lymphoma
Focus Registrational; Therapeutic Use
Acronyms GOLSEEK-1
Sponsors Celgene Corporation

12 Jun 2025 According to a Bristol Myers Squibb media release, results form this trial are expected in the 2028.
10 Dec 2024 Trial design presented at the 66th American Society of Hematology Annual Meeting and Exposition.
16 Jun 2024 Trial design presented at the 29th Congress of the European Haematology Association

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com